Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies

Author： Vekrellis Kostas   Stefanis Leonidas  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.16, Iss.4, 2012-04, pp. : 421-432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 2, 2012-03 ,pp. : 174-179

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease

By  

Current Pharmaceutical Design, Vol. 23, Iss. 33, 2018-01 ,pp. : 4936-4947

Bentham Science Publishers

Access to resources Recommend Favorite

Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures

By  

Current Pharmaceutical Design, Vol. 24, Iss. 20, 2018-06 ,pp. : 2317-2321

Bentham Science Publishers

Access to resources Recommend Favorite

-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 630-637

Bentham Science Publishers

Access to resources Recommend Favorite

Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 6, 2011-09 ,pp. : 693-702

Bentham Science Publishers

Access to resources Recommend Favorite